ATOSSA THERAPEUTICS, INC. (ATOS): Nasdaq/NYSE listing notice — Atossa gets 180-day NASDAQ extension to cure bid price deficiency

ATOSSA THERAPEUTICS, INC.

Received NASDAQ notice on Oct 5, 2022 for non-compliance with $1.00 minimum bid price rule.
Deadline extended by 180 days to October 2, 2023, per company request.
Company to monitor bid price and may consider reverse stock split if needed.
No immediate effect on listing or trading of common stock.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

ATOSSA THERAPEUTICS, INC. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: extension granted
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

April 4, 2023, the Company was informed that the deadline for compliance was extended by 180 days, or until October 2, 2023. The October 5, 2022 NASDAQ notice of noncompliance has no immediate effect on the listing or trading of the Company’s common stock on the NASDAQ Stock Market. The Company intends to actively monitor the bid price for its common stock between now and October 2, 2023, and will consider available options to resolve the deficiency and regain compliance with the minimum bid price requirement, including, if necessary, effectuating a reverse stock split. . * * * SIGNATURES Purs

View on SEC.gov

Browse all listing & compliance notices →

ATOSSA THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001437749-23-009194

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.